Jennifer Lachey, Chief Scientific Officer at Keros Therapeutics, Inc. (KROS), sold 8,698 shares at $41.26 ($362K) on 2022-05-11, disclosed to the SEC on 2022-05-13.
Open-market sale of $362k KROS by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $41.26 | 3,398 | $140K | 38.7% |
| 2 | $41.26 | 3,398 | $140K | 38.7% |
| 3 | $42.49 | 944 | $40K | 11.1% |
| 4 | $43.32 | 719 | $31K | 8.6% |
| 5 | $44.23 | 223 | $10K | 2.7% |
| 6 | $45.45 | 16 |
| $727 |
| 0.2% |
| Total | $41.65 avg | 8,698 | $362K | 100% |
| Filing → |
| KROS | SELL | 2022-04-13 | $630K | — | Filing → |
| KROS | SELL | 2022-04-06 | $477K | — | Filing → |
| KROS | SELL | 2022-03-15 | $197K | — | Filing → |